Atea Pharmaceuticals Förvaltning
Förvaltning kriterier kontrolleras 4/4
Atea Pharmaceuticals VD är Jean-Pierre Sommadossi, utsedd i Jul 2012, har en mandatperiod på 13.83 år. totala årliga ersättningen är $ 3.40M, bestående av 20.7% lön 79.3% bonusar, inklusive företagsaktier och optioner. äger direkt 8.29% av företagets aktier, värda $ 29.32M. Den genomsnittliga mandatperioden för ledningsgruppen och styrelsen är 5.8 år respektive 5.8 år.
Viktig information
Jean-Pierre Sommadossi
Verkställande direktör
US$3.4m
Total ersättning
| VD-lön i procent | 20.67% |
| Anställning som VD | 13.8yrs |
| Ägande av VD | 8.3% |
| Ledningens genomsnittliga anställningstid | 5.8yrs |
| Styrelsens genomsnittliga mandatperiod | 5.8yrs |
Senaste uppdateringar av ledningen
Recent updates
Hepatitis C Trial And Pricing Risks Will Dominate Outlook Yet Longer Term Potential Remains
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral antiviral therapies for hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?We Think Atea Pharmaceuticals (NASDAQ:AVIR) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Hepatitis Antiviral Pipeline Will Create Long Term Upside Potential
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals focuses on developing oral direct acting antiviral therapies for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?
Hepatitis C And E Antiviral Pipeline Will Reshape Long Term Outlook
Catalysts About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biotechnology company focused on developing oral direct acting antivirals for serious viral infections, including hepatitis C and hepatitis E. What are the underlying business or industry changes driving this perspective?Atea wins FDA Fast Track status for dengue treatment
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), a biotech focused on developing treatments for viral infections, announced Monday that the FDA granted Fast Track Designation to AT-752, an investigational oral therapy for dengue virus infection. Dengue is the most common mosquito-borne virus in the world, affecting an estimated up to 400M people annually. The FDA offers the Fast Track designation to accelerate the development and review of drugs targeted at serious conditions with unmet medical needs. It allows developers to communicate frequently with the regulator on plans for clinical studies. Developed using AVIR’s purine nucleotide prodrug platform, AT-752 is currently undergoing two proof-of-concept studies for dengue, with data expected at the end of the year. Read more on upcoming milestones for AVIR as outlined by the management in August.Atea Pharmaceuticals Q2 2022 Earnings Preview
Atea Pharmaceuticals (NASDAQ:AVIR) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.49 (-2550.0% Y/Y) and the consensus Revenue Estimate is $0M Over the last 3 months, EPS estimates have seen 2 upward revisions and 1 downward.Atea Pharmaceuticals, Inc.'s (NASDAQ:AVIR) Shares Not Telling The Full Story
When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 16x, you may...Analysts Just Shaved Their Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Forecasts Dramatically
Today is shaping up negative for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders, with the analysts delivering...Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Analysts Just Slashed Next Year's Estimates
The latest analyst coverage could presage a bad day for Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ), with the analysts...A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.A Look Into The Ownership Structure of Atea Pharmaceuticals (NASDAQ:AVIR)
Now and then, the volatility of the pharmaceutical sector rears its ugly head, leaving the hordes of investors running for the hills. Leading the decline this week was Atea Pharmaceuticals (NasdaqGS: AVIR) that lost over two-thirds of its value. We will look into this severe decline and reflect on the state of the ownership.Atea Pharmaceuticals' COVID Antiviral Trial Failure Hands Initiative To Merck's Molnupiravir
Atea Pharmaceuticals posted underwhelming data from a Phase 2 trial of its COVID antiviral therapy AT-527 on Oct. 19, causing its stock price to fall by 66%. The drug failed to meet its endpoint of reduction of the SARS-Cov-2 virus compared to placebo in a subset of patients - around two-thirds of whom were low risk. Atea has a similar mechanism of action to Merck's Molnupiravir, which looks likely to win Emergency Approval for mild-to-moderate COVID-19 patients who are at risk for progressing to severe COVID. If Atea management has used only unvaccinated patients with a serious underlying health issue, as Merck did, the outcome of its MOONSONG trial may have been different. As such, Atea may be able to alter pivotal trial protocols and still make it to market - although yesterday's data means that will not happen for at least another year, by which time, it may be too late.Analys av ersättningar till VD
| Datum | Total ersättning | Lön | Företagets resultat |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$170m |
| Dec 31 2025 | US$3m | US$703k | -US$158m |
| Sep 30 2025 | n/a | n/a | -US$147m |
| Jun 30 2025 | n/a | n/a | -US$136m |
| Mar 31 2025 | n/a | n/a | -US$139m |
| Dec 31 2024 | US$4m | US$703k | -US$168m |
| Sep 30 2024 | n/a | n/a | -US$174m |
| Jun 30 2024 | n/a | n/a | -US$176m |
| Mar 31 2024 | n/a | n/a | -US$164m |
| Dec 31 2023 | US$6m | US$683k | -US$136m |
| Sep 30 2023 | n/a | n/a | -US$131m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$109m |
| Dec 31 2022 | US$6m | US$650k | -US$116m |
| Sep 30 2022 | n/a | n/a | US$36m |
| Jun 30 2022 | n/a | n/a | US$16m |
| Mar 31 2022 | n/a | n/a | US$48m |
| Dec 31 2021 | US$34m | US$650k | US$121m |
| Sep 30 2021 | n/a | n/a | US$25m |
| Jun 30 2021 | n/a | n/a | US$35m |
| Mar 31 2021 | n/a | n/a | US$24m |
| Dec 31 2020 | US$3m | US$437k | -US$11m |
| Sep 30 2020 | n/a | n/a | -US$36m |
| Jun 30 2020 | n/a | n/a | -US$22m |
| Mar 31 2020 | n/a | n/a | -US$16m |
| Dec 31 2019 | US$811k | US$400k | -US$14m |
Ersättning vs marknad: Jean-Pierre s total kompensation ($USD 3.40M ) är ungefär genomsnittet för företag av liknande storlek på US marknaden ($USD 2.65M ).
Ersättning vs inkomst: Ersättningen från Jean-Pierre har varit i linje med företagets resultat under det senaste året.
VD OCH KONCERNCHEF
Jean-Pierre Sommadossi (69 yo)
Dr. Jean-Pierre Sommadossi, Ph D., is a Founder of Atea Pharmaceuticals, Inc. and has been its Chairman, Director, Chief Executive Officer and President since July 2012 and had been its Treasurer. Dr. Somm...
Ledningsgrupp
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 29.3m | |
| CFO, Executive VP of Legal & Secretary | 12.4yrs | US$1.69m | 1.03% $ 3.6m | |
| Chief Commercial Officer | 7.6yrs | US$1.22m | 0.21% $ 729.8k | |
| Chief Development Officer | 5.8yrs | US$1.77m | 0.16% $ 564.3k | |
| Chief Medical Officer | 5.8yrs | US$1.59m | 0.12% $ 424.7k | |
| Executive VP of Finance & Chief Accounting Officer | 4.3yrs | US$1.52m | 0.099% $ 350.6k | |
| Senior Vice President of Investor Relations & Corporate Communications | 5.3yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Chemistry | no data | inga uppgifter | inga uppgifter | |
| Executive Vice President of Early Stage Development | no data | inga uppgifter | inga uppgifter | |
| Executive VP of Clinical Sciences & Project Management | 6.3yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Regulatory Affairs | 5.3yrs | inga uppgifter | inga uppgifter | |
| Executive Vice President of Preclinical Development | 4.3yrs | inga uppgifter | inga uppgifter |
Erfaren ledning: AVIR s ledningsgrupp är erfaren och erfaren ( 5.8 års genomsnittlig anställning).
Styrelseledamöter
| Namn | Position | Anställning | Kompensation | Ägarskap |
|---|---|---|---|---|
| Founder | 13.8yrs | US$3.40m | 8.29% $ 29.3m | |
| Independent Director | 1.3yrs | US$415.33k | 0.057% $ 202.0k | |
| Independent Director | 5.6yrs | US$256.90k | 0.078% $ 277.4k | |
| Independent Director | 11.7yrs | US$249.40k | 0.14% $ 498.4k | |
| Lead Independent Director | 6.7yrs | US$282.90k | 0.63% $ 2.2m | |
| Independent Director | 11.5yrs | US$249.40k | 0.12% $ 420.8k | |
| Independent Director | 5.8yrs | US$251.90k | 0.11% $ 380.3k | |
| Independent Director | 5yrs | US$366.90k | 0.078% $ 277.4k | |
| Independent Director | less than a year | US$407.11k | inga uppgifter |
Erfaren styrelse: AVIR s styrelse anses vara erfaren ( 5.8 års genomsnittlig mandatperiod).
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/24 00:59 |
| Aktiekurs vid dagens slut | 2026/05/22 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Atea Pharmaceuticals, Inc. bevakas av 4 analytiker. 2 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Eric Joseph | J.P. Morgan |
| Matthew Harrison | Morgan Stanley |
| Maxwell Skor | Morgan Stanley |